Here are the 424B prospectus supplements from Arbe Robotics Ltd. (ARBE) in our archive over the last 12 months, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 424B covers the supplement that carries the terms of a priced offering, so if you follow ARBE and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full ARBE filings page.
Arbe Robotics Ltd. is offering 833,334 ordinary shares and pre-funded warrants to purchase up to 24,166,666 ordinary shares. The ordinary shares are priced at $0.60 each; each pre-funded warrant costs $0.5999 and is immediately exercisable for one share at $0.0001. Arbe estimates net proceeds of approximately $13.8 million after underwriting discounts, commissions and offering expenses, for working capital and general corporate purposes, including scaling operations, defense and counter-drone expansion, and potential acquisitions.
New investors face immediate net tangible book value dilution of $0.24 per share. Warrant holders may not exercise if doing so would put them and affiliates above 4.99% ownership, or an elected limit up to 9.99%; cashless exercise is permitted, and no trading market is expected. Arbe expects only nominal proceeds, if any, from later warrant exercises. A Nasdaq notice received April 13, 2026, said the closing bid price had been below $1.00 for 30 consecutive business days; Arbe has until October 12, 2026, to regain compliance by meeting at least $1.00 per share for at least 10 consecutive business days. Delivery is expected on or about September 28, 2026, subject to customary closing conditions.
Arbe Robotics Ltd. is conducting a primary offering of 11,500,000 ordinary shares at $1.40 per share under its shelf registration. The underwriters have a 30‑day option to buy up to 1,725,000 additional shares, which would increase the deal size if fully exercised.
The company expects gross proceeds of $16.1 million and approximately $15.1 million in proceeds before expenses, or $17.4 million if the option is fully exercised. After underwriting fees and estimated expenses, net proceeds are estimated at about $14.8 million, or $17.1 million with full option exercise.
Arbe plans to use the cash for working capital and general corporate purposes108,859,502 as of September 30, 2025 and are expected to be 120,359,502 after the offering, or 122,084,502 if the option is fully exercised, meaning existing holders are diluted but the company gains additional funding to support its 4D imaging radar business.